Freedom Broker raises Pfizer stock price target on strong Q3 results

Investing.com · 2026-11-06 14:56 UTC

Freedom Broker raises Pfizer stock price target on strong Q3 results

Investing.com - Freedom Broker raised its price target on Pfizer Inc. (NYSE:PFE) to $34 from $33 while maintaining a Buy rating on the stock. With shares currently trading at $29.19, InvestingPro analysis suggests the stock remains undervalued based on its Fair Value assessment, placing it among opportunities on the Most Undervalued list.

The firm cited Pfizer’s third-quarter 2026 results as strong, with revenue and earnings per share materially ahead of its estimates. The outperformance was driven by broad-based strength across the core business. The pharmaceutical giant has delivered a 26% year-to-date return and is trading near its 52-week high of $31.44, reflecting growing investor confidence.

Eliquis, Vyndaqel, and Padcev were the key contributors to the quarter’s performance. The COVID franchise sales fell short of Freedom Broker’s expectations.

Read the full story at Investing.com · All coverage of this story